Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

15.44
+0.58003.90%
Volume:3.85M
Turnover:59.17M
Market Cap:3.98B
PE:4.64
High:15.62
Open:14.85
Low:14.70
Close:14.86
Loading ...

Barclays Sticks to Its Buy Rating for Organon (OGN)

TIPRANKS
·
3 hours ago

May Health Appoints Seasoned Medtech Executive, Colby Holtshouse, as President and CEO

THOMSON REUTERS
·
7 hours ago

Organon announes results from analysis of Phase 3 ADORING 3 study

TIPRANKS
·
12 hours ago

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire
·
08 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.
·
17 Feb

Organon & Co. Navigates Growth Amidst Challenges

TIPRANKS
·
17 Feb

Organon Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
15 Feb

Organon & Is Maintained at Overweight by Barclays

Dow Jones
·
14 Feb

Bank of America Securities Reaffirms Their Sell Rating on Organon (OGN)

TIPRANKS
·
14 Feb

Morgan Stanley Keeps Their Hold Rating on Organon (OGN)

TIPRANKS
·
14 Feb

Organon price target lowered to $24 from $26 at Barclays

TIPRANKS
·
14 Feb

BUZZ-Organon rises on Q4 profit beat

Reuters
·
14 Feb

Stock Track | Organon & Co (OGN) Soars 8.98% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track
·
13 Feb

Organon & Co reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Organon's Q4 Adjusted Earnings Rise, Revenue Declines; 2025 Sales Guidance Set

MT Newswires Live
·
13 Feb